Kunshan Asia Aroma Corp. Ltd. (301220) - Total Liabilities

Latest as of June 2025: CN¥682.01 Million CNY ≈ $99.80 Million USD

Based on the latest financial reports, Kunshan Asia Aroma Corp. Ltd. (301220) has total liabilities worth CN¥682.01 Million CNY (≈ $99.80 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Kunshan Asia Aroma Corp. Ltd. to assess how effectively this company generates cash.

Kunshan Asia Aroma Corp. Ltd. - Total Liabilities Trend (2019–2024)

This chart illustrates how Kunshan Asia Aroma Corp. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check 301220 financial resilience to evaluate the company's liquid asset resilience ratio.

Kunshan Asia Aroma Corp. Ltd. Competitors by Total Liabilities

The table below lists competitors of Kunshan Asia Aroma Corp. Ltd. ranked by their total liabilities.

Company Country Total Liabilities
Cimentas Izmir Cimento Fabrikasi TAS
IS:CMENT
Turkey TL5.93 Billion
Weebit Nano Ltd
AU:WBT
Australia AU$6.77 Million
Plan B Media PCL
BK:PLANB
Thailand ฿6.88 Billion
Loctek Ergonomic Technology Corp Class A
SHE:300729
China CN¥6.49 Billion
Nantong Square Cold Chain Equipment Co Ltd
SHG:603339
China CN¥930.99 Million
Attacq
JSE:ATT
South Africa ZAC9.24 Billion
Zhe Jiang Li Zi Yuan Food Co Ltd
SHG:605337
China CN¥1.59 Billion

Liability Composition Analysis (2019–2024)

This chart breaks down Kunshan Asia Aroma Corp. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kunshan Asia Aroma Corp. Ltd. stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.47 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Kunshan Asia Aroma Corp. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Kunshan Asia Aroma Corp. Ltd. (2019–2024)

The table below shows the annual total liabilities of Kunshan Asia Aroma Corp. Ltd. from 2019 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥464.68 Million
≈ $68.00 Million
+77.42%
2023-12-31 CN¥261.90 Million
≈ $38.32 Million
+43.60%
2022-12-31 CN¥182.38 Million
≈ $26.69 Million
-43.14%
2021-12-31 CN¥320.73 Million
≈ $46.93 Million
-4.87%
2020-12-31 CN¥337.16 Million
≈ $49.34 Million
+12.50%
2019-12-31 CN¥299.70 Million
≈ $43.85 Million
--

About Kunshan Asia Aroma Corp. Ltd.

SHE:301220 China Chemicals
Market Cap
$619.15 Million
CN¥4.23 Billion CNY
Market Cap Rank
#11447 Global
#3466 in China
Share Price
CN¥37.52
Change (1 day)
-2.11%
52-Week Range
CN¥35.23 - CN¥76.41
All Time High
CN¥88.60
About

Kunshan Asia Aroma Corp., Ltd. engages in the research and development, production, and sale of spices and food additives in China. It offers natural ingredients, which include Acetaldehyde NAT, Octanal NAT, Nonanal NAT, 2-Methylbutyric Acid NAT, Ethyl 2-Methylbutyrate NAT, Vanillin Ex Eugenol NAT, Vanillin Ex Ferulic Acid NAT, Leaf alcohol NAT, Cis-3-Hexenyl Acetate NAT, Cis-3-Hexenyl Butyrate N… Read more